Business Wire

rf IDEAS Launches End-to-End FIDO2 Credential Solution with IDmelon

6.3.2023 18:30:00 EET | Business Wire | Press release

Share

rf IDEAS, a leading manufacturer of credential readers for authentication and logical access, is pleased to announce the release of the rf IDEAS FIDO2 Passwordless Platform powered by IDmelon. This end-to-end solution brings seamless, passwordless authentication to existing credentials by converting them to FIDO2 security keys – overnight.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230306005278/en/

FIDO2 frees organizations from password management and risk

Nearly 90% of data breaches are due to stolen passwords or human error. Passwordless single-sign on solutions are helping to combat this challenge, and migrating to more secure credentials helps arm your team with a defense mechanism.

“Partnering with rf IDEAS, and their WAVE ID® technology was a strategic decision for IDmelon – leveraging the trust and reliability of their readers to bring the FIDO2 Passwordless Platform to market allows us to jointly deliver an end-to-end solution that organizations can deploy quickly and scale affordably,” remarked CEO and co-founder of IDmelon Bahram Piri.

The rf IDEAS FIDO2 Passwordless Platform eliminates the need for centrally stored passwords that can be hacked, as well as the risk of password theft, phishing and other user-directed cyberattacks. And for users, it’s simple to roll out and easy to use. Organizations can now enable and manage passwordless authentication across credential types, devices and platforms. This rapidly growing industry standard is supported by Microsoft, Google, Apple, and all leading web services and browsers.

Ushering in a new standard for authentication

The logical access control industry is evolving rapidly to combat cyber threats and data breaches while improving the user experience of authentication without risking governance and security.

“At rf IDEAS, we have listened to our customers and are proud to release a solution that removes the complexities of credential migration, converting users quickly and securely to a higher standard of security,” said Raul Cepeda Jr., Vice President of Product and Marketing at rf IDEAS. “Now, access via security keys is possible using existing credentials, WAVE ID readers, and the rf IDEAS Passwordless Platform – evolving the way we think about migration across credentials by leveraging ID badges and smartphones to unlock potential to more secure authentication methods.”

rf IDEAS and IDmelon will be showcasing their joint solution at the upcoming Gartner IAM symposiums in London and Texas this month – to see a full listing of upcoming events visit our Events Page.

To learn more and set up a 1:1 consultation, visit rfIDEAS.com/FIDO2.

About rf IDEAS

rf IDEAS, Inc. is a leader in logical access solutions for healthcare, manufacturing, financial, government, education and enterprise. The company’s WAVE ID readers are trusted by users across the globe and backed by strong partnerships with leading identity and access management providers. rf IDEAS readers enable innovative solutions for single sign-on, secure printing, and mobile authentication while supporting nearly all credentials worldwide. For more information, visit www.rfIDEAS.com .

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Megan Forsberg
P: 224-236-0270 x 1479
E: mforsberg@rfIDEAS.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 12:00:00 EEST | Press release

WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, uses biomarker data, including temperature and heart rate data, to identify fertile and non-fertile days, helping users prevent pregnancy without hormones while also providing fertility insights. Beyond birth control, the app

Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 11:00:00 EEST | Press release

Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphatax's long-term vision for the future of tax technology. By bringing these transfer pric

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release

Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release

Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye